Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1398

Shown on this page

Current sort

Live official records

Conditions: Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
Interventions: Emapalumab, Fludarabine and Dexamethasone, Allogeneic hematopoietic stem cell transplant (allo-HCT); Drug · Procedure
Lead sponsor: Joseph Oved; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: San Francisco, California • Atlanta, Georgia • Basking Ridge, New Jersey + 9 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: SX-682, Enzalutamide; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 3 more

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more

Conditions: Chronic Kidney Disease (CKD)
Interventions: Vonsetamig; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 7 more

Conditions: Metastatic Prostate Cancer, Prostate Cancer
Interventions: 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire; Drug · Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions: taldefgrobep alfa, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Type 1 Diabetes
Interventions: Normal Glycemia Goal, Tight Glycemia Goal; Device
Lead sponsor: Mark D. DeBoer, MD, MSc., MCR; Other
Eligibility: 6 Years to 13 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: NAFLD, PCOS
Interventions: Bicalutamide 50 mg, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
Interventions: KPT-330; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Months to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Multifocal Motor Neuropathy
Interventions: Not listed
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 21 more

About this UCSF institution page

What this page lists: ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCSF

Filter and sort this campus

Live official records

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

AIDANET Pediatrics

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Bicalutamide Therapy in Young Women With NAFLD and PCOS

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

About this UCSF institution page